---
title: "Key facts: BioVie Inc. reports $6.1M Q4 loss; faces operational issues"
description: "BioVie Inc. posted a net loss of $6.1 million for Q4 2025, a $1.0 million drop from Q4 2024, mainly due to reduced research and admin costs.1BioVie faces operational and financial issues, including cl"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275210149.md"
published_at: "2026-02-07T20:03:01.000Z"
---

# Key facts: BioVie Inc. reports $6.1M Q4 loss; faces operational issues

> BioVie Inc. posted a net loss of $6.1 million for Q4 2025, a $1.0 million drop from Q4 2024, mainly due to reduced research and admin costs.1BioVie faces operational and financial issues, including clinical programs and legal matters, along with recent actions like a reverse stock split and plans for a spin-off.2

-   BioVie Inc. posted a net loss of $6.1 million for Q4 2025, a $1.0 million drop from Q4 2024, mainly due to reduced research and admin costs.1
-   BioVie faces operational and financial issues, including clinical programs and legal matters, along with recent actions like a reverse stock split and plans for a spin-off.2

### Related Stocks

- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [BIVI.US - Biovie](https://longbridge.com/en/quote/BIVI.US.md)
- [LABD.US - Direxion S&P Biotech Bear 3X](https://longbridge.com/en/quote/LABD.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments | Vertex Pharmaceuticals forecasts 2026 revenue between $12.95 billion and $13.1 billion, aligning with analysts' estimate | [Link](https://longbridge.com/en/news/275806330.md) |
| Nasdaq Warns Abpro Holdings of Possible Delisting Over Board Compliance Lapses | Abpro Holdings Inc. is at risk of being delisted from the Nasdaq due to noncompliance with Listing Rules after two board | [Link](https://longbridge.com/en/news/275658950.md) |
| Biovica Study Confirms DiviTum TKa Prognostic Value in Metastatic Breast Cancer | Biovica International AB has published new clinical data confirming the prognostic value of its DiviTum® TKa assay in me | [Link](https://longbridge.com/en/news/275716493.md) |
| IGC Pharma erweitert Alzheimer-Studie nach Kolumbien | IGC Pharma Inc. is expanding its Phase 2 CALMA study for Alzheimer's treatment by collaborating with the renowned Grupo  | [Link](https://longbridge.com/en/news/275324973.md) |
| Aprea Therapeutics Secures New Patents in Australia and Japan to Strengthen Global DDR Cancer Therapy Portfolio | Aprea Therapeutics has secured new patents in Australia and Japan, enhancing its global intellectual property for its DN | [Link](https://longbridge.com/en/news/275688060.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.